• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glaukos shares fall on Q2 sales, EPS miss

August 3, 2017 By Fink Densford

Glaukos logo

Shares in Glaukos (NYSE:GKOS) have fallen today after the diabetes-focused medical device maker missed expectation on Wall Street with its 2nd quarter earnings results.

The San Clemente, Calif.-based company posted losses of $3.3 million, or 10¢ per share, on sales of $41.3 million for the 3 months ended June 30, seeing profits swing 241.6% into losses while sales grew 44.6% compared with the same period last year.

Losses per share were significantly off from 5¢ earnings per share expectations on Wall Street, where analysts were expecting to see revenue of $39.7 million.

“These results represent another quarter of record performance for Glaukos shareholders and reflect the continued successful execution of our growth strategy. We remain fully focused on increasing global adoption of our iStent and iStent inject Trabecular Micro Bypass Stents by growing the ranks of trained surgeons, helping them integrate the technology into their practices, and expanding the body of compelling clinical evidence that underscores the benefits of our micro-scale glaucoma technology to patients, practitioners and payors. In addition, we continue to advance our industry-leading pipeline of micro-scale innovations designed to transform glaucoma therapy,” prez & CEO Thomas Burns said in a press release.

Glaukos reaffirmed its 2017 sales guidance, expecting to post between $162 million and $167 million for the full year, up 42% to 46% over the previous year.

Shares in Glaukos have fallen 4.7% so far today, at $37.88 as of 2:46 p.m. EDT.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Glaukos

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS